Clinical trials for glioblastoma multiforme using adenoviral vectors

Current Opinion in Molecular Therapeutics

Volumn 11, Issue 5, 2009, Pages 485-492

  Wirth, T ^a   Samaranayake, H ^a,b   Pikkarainen, J ^a,b   Maatta A M ^b   Yla Herttuala S ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Finland Ark Therapeutics Oy   (Finland)

Author keywords

Adenoviral vector; Cerepro; Gene therapy; Glioma; HSV tk; Sitimagene ceradenovec

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEREPRO; CONDITIONALLY REPLICATING HERPES SIMPLEX VIRUS 1 G207; GANCICLOVIR; GENDICINE; H 101; HERPESVIRUS VECTOR; IRINOTECAN; ONCORINE; PLASMID DNA; RETROVIRUS VECTOR; SITIMAGENE CERADENOVEC; TEMOZOLOMIDE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

APHASIA; BRAIN CANCER; BRAIN EDEMA; BYSTANDER EFFECT; CANCER GENE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; FEVER; GENE TRANSFER; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMIPARESIS; HUMAN; LIPOFECTION; MEASLES VIRUS; NEURAL STEM CELL; NEWCASTLE DISEASE PARAMYXOVIRUS; POLIOMYELITIS VIRUS; PROGNOSIS; RADIATION DOSE; REVIEW; RNA TRANSFECTION; SEIZURE; SEMLIKI FOREST ALPHAVIRUS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME;

ADENOVIRIDAE; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

SIMPLEXVIRUS;

EID: 70349900808     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Ohgaki H: Epidemiology of brain tumors. Methods Mol Biol (2009) 472:323-342.
2. Ohgaki H, Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol (2007) 170(5):1445-1453.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 114(2):97-109.
4. Collins VP: Brain tumours: Classification and genes. J Neurol Neurosurg Psychiatry (2004) 75(Suppl 2):ii2-11.
5. Nakamura M, Shimada K, Ishida E, Nakase H, Konishi N: Genetic analysis to complement histopathological diagnosis of brain tumors. Histol Histopathol (2007) 22(3):327-335. (Pubitemid 46117119)
6. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 10(5):459-466. •• Latest results of a randomized phase III clinical trial evaluating the effects of radiation therapy with concomitant and adjuvant temozolomide.
7. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2009) 27(5):740-745.
8. Genentech Inc: FDA grants accelerated approval of Avastin for brain cancer (glioblastoma) that has progressed following prior therapy. Press Release (2009):May 06.
9. Castro MG, Cowen R, Williamson IK, David A, Jimenez-Dalmaroni MJ, Yuan X, Bigliari A, Williams JC, Hu J, Lowenstein PR: Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther (2003) 98(1):71-108. (Pubitemid 36349762)
10. Beduneau A, Saulnier P, Benoit JP: Active targeting of brain tumors using nanocarriers. Biomaterials (2007) 28(33):4947-4967. (Pubitemid 47362345)
11. Claes A, Wesseling P, Jeuken J, Maass C, Heerschap A, Leenders WP: Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther (2008) 7(1):71-78.
12. de Vries NA, Beijnen JH, Boogerd W, van Tellingen O: Blood-brain barrier and chemotherapeutic treatment of brain tumors. Expert Rev Neurother (2006) 6(8):1199-1209. (Pubitemid 44231977)
13. Ylä-Herttuala S, Alitalo K: Gene transfer as a tool to induce therapeutic vascular growth. Nat Med (2003) 9(6):694-701. • Comprehensive review on gene therapy and the use of gene therapy to induce therapeutic vascular growth using different growth factors.
14. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL: Gene transfer into humans - Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 323(9):570-578.
15. Mountain A: Gene therapy: The first decade. Trends Biotechnol (2000) 18(3):119-128.
16. Kohn DB, Candotti F: Gene therapy fulfilling its promise. N Engl J Med (2009) 360(5):518-521.
17. Gene therapy clinical trials worldwide: John Wiley & Sons Inc, Chichester, UK (2009). www.wiley.co.uk/genetherapy/clinical/
18. Räty JK, Pikkarainen JT, Wirth T, Ylä-Herttuala S: Gene therapy: The first approved gene-based medicines, molecular mechanisms and clinical indications. Curr Mol Pharmacol (2008) 1(1):13-23.
19. Pulkkanen KJ, Ylä-Herttuala S: Gene therapy for malignant glioma: Current clinical status. Mol Ther (2005) 12(4):585-598. (Pubitemid 41350140)
20. Immonen A, Vapalahti M, Tyynela K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N, Ylä-Herttuala S: AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol Ther (2004) 10(5):967-972. (Pubitemid 39419922)
21. Aghi M, Chiocca EA: Gene therapy for glioblastoma. Neurosurg Focus (2006) 20(4):E18.
22. Lawler SE, Peruzzi PP, Chiocca EA: Genetic strategies for brain tumor therapy. Cancer Gene Ther (2006) 13(3):225-233. (Pubitemid 43255759)
23. King GD, Curtin JF, Candolfi M, Kroeger K, Lowenstein PR, Castro MG: Gene therapy and targeted toxins for glioma. Curr Gene Ther (2005) 5(6):535-557. (Pubitemid 43009500)
24. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D et al: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med (1997) 3(12):1354-1361. (Pubitemid 28011035)
25. Asadi-Moghaddam K, Chiocca EA: Gene- and viral-based therapies for brain tumors. Neurotherapeutics (2009) 6(3):547-557. • Comprehensive review on gene therapy approaches and vectors used for treatment of brain tumors.
26. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther (1993) 4(1):39-69. (Pubitemid 223002217)
27. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN et al: Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther (2009) 17(1):199-207.
28. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther (2000) 7(10):867-874. (Pubitemid 30303584)
29. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science (1997) 275(5304):1320-1323. (Pubitemid 27114163)
30. Hong SS, Karayan L, Tournier J, Curiel DT, Boulanger PA: Adenovirus type 5 fiber knob binds to MHC class I α2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J (1997) 16(9):2294-2306. (Pubitemid 27258631)
31. Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G: Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology (2000) 268(2):382-390. (Pubitemid 30159987)
32. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G: Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol (2001) 75(18):8772-8780. (Pubitemid 32768981)
33. Chu Y, Heistad D, Cybulsky MI, Davidson BL: Vascular cell adhesion molecule-1 augments adenovirus-mediated gene transfer. Arterioscler Thromb Vasc Biol (2001) 21(2):238-242.
34. Meier O, Boucke K, Hammer SV, Keller S, Stidwill RP, Hemmi S, Greber UF: Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J Cell Biol (2002) 158(6):1119-1131. (Pubitemid 35052694)
35. Zhang Y, Bergelson JM: Adenovirus receptors. J Virol (2005) 79(19):12125-12131.
36. Seshidhar Reddy P, Ganesh S, Limbach MP, Brann T, Pinkstaff A, Kaloss M, Kaleko M, Connelly S: Development of adenovirus serotype 35 as a gene transfer vector. Virology (2003) 311(2):384-393. (Pubitemid 36808779)
37. Wirth T, Ylä-Herttuala S: Gene technology based therapies in the brain. Adv Tech Stand Neurosurg (2006) 31:3-32.
38. Raty JK, Lesch HP, Wirth T, Ylä-Herttuala S: Improving safety of gene therapy. Curr Drug Saf (2008) 3(1):46-53.
39. Wirth T, Hedman M, Makinen K, Manninen H, Immonen A, Vapalahti M, Ylä-Herttuala S: Safety profile of plasmid/liposomes and virus vectors in clinical gene therapy. Curr Drug Saf (2006) 1(3):253-257.
40. Lehrman S: Virus treatment questioned after gene therapy death. Nature (1999) 401(6753):517-518.
41. Imperiale MJ, Kochanek S: Adenovirus vectors: Biology, design, and production. Curr Top Microbiol Immunol (2004) 273:335-357. (Pubitemid 37203637)
42. Danthinne X, Imperiale MJ: Production of first generation adenovirus vectors: A review. Gene Ther (2000) 7(20):1707-1714. (Pubitemid 30821568)
43. Bett AJ, Prevec L, Graham FL: Packaging capacity and stability of human adenovirus type 5 vectors. J Virol (1993) 67(10):5911-5921. (Pubitemid 23277501)
44. Bett AJ, Haddara W, Prevec L, Graham FL: An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA (1994) 91(19):8802-8806.
45. Verma IM, Weitzman MD: Gene therapy: Twenty-first century medicine. Annu Rev Biochem (2005) 74:711-738.
46. McKnight SL: The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene. Nucleic Acids Res (1980) 8(24):5949-5964. (Pubitemid 11100297)
47. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res (1986) 46(10):5276-5281. •• Important paper suggesting the use of HSV-tk for cancer therapy.
48. Moolten FL, Wells JM: Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst (1990) 82(4):297-300.
49. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 256(5063):1550-1552.
50. Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH: In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res (1993) 53(1):83-88. (Pubitemid 23019380)
51. Palmer DH, Young LS, Mautner V: Cancer gene-therapy: Clinical trials. Trends Biotechnol (2006) 24(2):76-82.
52. Aghi M, Hochb erg F, Breakefield XO: Prodrug activation enzymes in cancer gene therapy. J Gene Med (2000) 2(3):148-164.
53. Kianmanesh AR, Perrin H, Panis Y, Fabre M, Nagy HJ, Houssin D, Klatzmann D: A 'distant' bystander effect of suicide gene therapy: Regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther (1997) 8(15):1807-1814.
54. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H: Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer (1997) 71(2):267-274. (Pubitemid 27253001)
55. Patel K, Trivedi S, Luo S, Zhu X, Pal D, Kern ER, Mitra AK: 55. Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir. Int J Pharm (2005) 305(1-2):75-89. (Pubitemid 41562219)
56. Portsmouth D, Hlavaty J, Renner M: Suicide genes for cancer therapy. Mol Aspects Med (2007) 28(1):4-41.
57. Barba D, Hardin J, Sadelain M, Gage FH: Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA (1994) 91(10):4348-4352. (Pubitemid 24143430)
58. Rainov NG, Kramm CM, Banning U, Riemann D, Holzhausen HJ, Heidecke V, Burger KJ, Burkert W, Korholz D: Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme. Gene Ther (2000) 7(21):1853-1858. (Pubitemid 30950183)
59. Colombo BM, Benedetti S, Ottolenghi S, Mora M, Pollo B, Poli G, Finocchiaro G: The 'bystander effect': Association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice. Hum Gene Ther (1995) 6(6):763-772. • Important paper demonstrating the bystander effect in vitro.
60. Hamel W, Magnelli L, Chiarugi VP, Israel MA: Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res (1996) 56(12):2697-2702. (Pubitemid 26175720)
61. Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD, Klatzmann D, Lassmann H, Castro MG, Lowenstein PR: Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. Nat Med (1999) 5(11):1256-1263. (Pubitemid 29535602)
62. Tomicic MT, Thust R, Kaina B: Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: Critical role of DNA breaks, Bcl-2 decline and caspase-9 activation. Oncogene (2002) 21(14):2141-2153. (Pubitemid 34311368)
63. Thust R, Schacke M, Wutzler P: Cytogenetic genotoxicity of antiherpes virostatics in Chinese hamster V79-E cells. I. Purine nucleoside analogues. Antiviral Res (1996) 31(1-2):105-113. (Pubitemid 26184463)
64. Halloran PJ, Fenton RG: 64. Irreversible G2-M arrest and cytoskeletal reorganization induced by cytotoxic nucleoside analogues. Cancer Res (1998) 58(17):3855-3865.
65. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN: The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res (1993) 53(21):5274-5283.
66. Wu JK, Cano WG, Meylaerts SA, Qi P, Vrionis F, Cherington V: Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery (1994) 35(6):1094-1102; discussion 1102-1103. (Pubitemid 24371196)
67. Sandmair AM, Turunen M, Tyynela K, Loimas S, Vainio P, Vanninen R, Vapalahti M, Bjerkvig R, Janne J, Ylä-Herttuala S: Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: Effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions. Cancer Gene Ther (2000) 7(3):413-421. (Pubitemid 30210408)
68. Tyynela K, Sandmair AM, Turunen M, Vanninen R, Vainio P, Kauppinen R, Johansson R, Vapalahti M, Ylä-Herttuala S: Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model. Cancer Gene Ther (2002) 9(11):917-924. (Pubitemid 35278564)
69. Vincent AJ, Vogels R, Someren GV, Esandi MC, Noteboom JL, Avezaat CJ, Vecht C, Bekkum DW, Valerio D, Bout A, Hoogerbrugge PM: Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors. Hum Gene Ther (1996) 7(2):197-205. (Pubitemid 26044838)
70. Perez-Cruet MJ, Trask TW, Chen SH, Goodman JC, Woo SL, Grossman RG, Shine HD: Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res (1994) 39(4):506-511. (Pubitemid 24348304)
71. Maatta AM, Tenhunen A, Pasanen T, Merilainen O, Pellinen R, Makinen K, Alhava E, Wahlfors J: Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy. Int J Oncol (2004) 24(4):943-949.
72. Pulkkanen KJ, Parkkinen JJ, Laukkanen JM, Kettunen MI, Tyynela K, Kauppinen RA, Ala-Opas MY, Ylä-Herttuala S: HSV-tk gene therapy for human renal cell carcinoma in nude mice. Cancer Gene Ther (2001) 8(7):529-536. (Pubitemid 32737840)
73. Asklund T, Appelskog IB, Ammerpohl O, Langmoen IA, Dilber MS, Aints A, Ekstrom TJ, Almqvist PM: Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp Cell Res (2003) 284(2):185-195. (Pubitemid 36329174)
74. Touraine RL, Vahanian N, Ramsey WJ, Blaese RM: Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum Gene Ther (1998) 9(16):2385-2391. (Pubitemid 28523987)
75. Mesnil M, Piccoli C, Tiraby G, Willecke K, Yamasaki H: Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA (1996) 93(5):1831-1835. (Pubitemid 26079840)
76. Elshami AA, Saavedra A, Zhang H, Kucharczuk JC, Spray DC, Fishman GI, Amin KM, Kaiser LR, Albelda SM: Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther (1996) 3(1):85-92.
77. Dilber MS, Abedi MR, Christensson B, Bjorkstrand B, Kidder GM, Naus CC, Gahrton G, Smith CI: Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res (1997) 57(8):1523-1528. (Pubitemid 27175570)
78. Princen F, Robe P, Lechanteur C, Mesnil M, Rigo JM, Gielen J, Merville MP, Bours V: A cell type-specific and gap junction-independent mechanism for the herpes simplex virus-1 thymidine kinase gene/ganciclovir-mediated bystander effect. Clin Cancer Res (1999) 5(11):3639-3644.
79. Imaizumi K, Hasegawa Y, Kawabe T, Emi N, Saito H, Naruse K, Shimokata K: Bystander tumoricidal effect and gap junctional communication in lung cancer cell lines. Am J Respir Cell Mol Biol (1998) 18(2):205-212. (Pubitemid 128355194)
80. Burrows FJ, Gore M, Smiley WR, Kanemitsu MY, Jolly DJ, Read SB, Nicholas T, Kruse CA: Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells. Cancer Gene Ther (2002) 9(1):87-95. (Pubitemid 34052857)
81. Kruse CA, Lamb C, Hogan S, Smiley WR, Kleinschmidt-Demasters BK, Burrows FJ: Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms. Cancer Gene Ther (2000) 7(1):118-127. (Pubitemid 30080995)
82. Ram Z, Walbridge S, Shawker T, Culver KW, Blaese RM, Oldfield EH: The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg (1994) 81(2):256-260. (Pubitemid 24238006)
83. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynela K, Turunen M, Vanninen R, Lehtolainen P et al: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther (2000) 11(16):2197-2205. •• The first controlled clinical trial demonstrating a significant survival advantage using HSV-tk gene therapy.
84. Rainov NG, Kramm CM, Aboody-Guterman K, Chase M, Ueki K, Louis DN, Harsh GR 4th, Chiocca A, Breakefield XO: Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther (1996) 3(2):99-106.
85. Rainov NG: A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther (2000) 11(17):2389-2401. • Important paper describing a phase III clinical trial, which demonstrated a lack of efficacy using VPCs in the treatment of MGs.
86. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimber K, Recio A, Knox L, Wilson JM, Albelda SM, Kaiser LR: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther (1998) 9(7):1083-1092.
87. Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, Hamilton WJ, Rojas-Martinez A, Chen SH, Woo SL, Grossman RG: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther (2000) 1(2):195-203.
88. Harsh GR, Deisboeck TS, Louis DN, Hilton J, Colvin M, Silver JS, Qureshi NH, Kracher J, Finkelstein D, Chiocca EA, Hochberg FH: Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: A gene-marking and neuropathological study. J Neurosurg (2000) 92(5):804-811. (Pubitemid 30243929)
89. Shand N, Weber F, Mariani L, Bernstein M, Gianella-Borradori A, Long Z, Sorensen AG, Barbier N: A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum Gene Ther (1999) 10(14):2325-2335.
90. Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C: Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther (2003) 7(6):851-858. (Pubitemid 36790262)
91. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K, Diquet B, Salzmann JL, Philippon J: A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther (1998) 9(17):2595-2604. (Pubitemid 29004632)
92. Valery CA, Seilhean D, Boyer O, Marro B, Hauw JJ, Kemeny JL, Marsault C, Philippon J, Klatzmann D: Long-term survival after gene therapy for a recurrent glioblastoma. Neurology (2002) 58(7):1109-1112. (Pubitemid 34298557)
93. Ark Therapeutics's Preliminary Cerepro Phase III Results Meet Primary Endpoint: BioSpace Inc (2008). www.biospace.com/news-story.aspx?NewsEntityId= 105049
94. Ark Therapeutics Group plc: Preliminary Cerepro(R) phase III results meet primary endpoint- Secondary endpoints yet to be established with 45% of patients still alive. Press Release (2008): July 30.
95. Hedman M, Muona K, Hedman A, Kivela A, Syvanne M, Eranen J, Rantala A, Stjernvall J, Nieminen MS, Hartikainen J, Ylä-Herttuala S: Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther (2009) 16(5):629-634. •• Important paper demonstrating the safety of gene therapy using Ad vectors.
96. Germano IM, Fable J, Gultekin SH, Silvers A: Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: Preliminary results of a phase I trial in patients with recurrent malignant gliomas. J Neurooncol (2003) 65(3):279-289. (Pubitemid 37526820)
97. Sandmair AM, Loimas S, Poptani H, Vainio P, Vanninen R, Turunen M, Tyynela K, Vapalahti M, Yla-Herttuala S: Low efficacy of gene therapy for rat BT4C malignant glioma using intra-tumoural transduction with thymidine kinase retrovirus packaging cell injections and ganciclovir treatment. Acta Neurochir (Wien) (1999) 141(8):867-872; discussion 872-873. (Pubitemid 29408429)
98. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, Baeza N et al: Genetic pathways to glioblastoma: A population-based study. Cancer Res (2004) 64(19):6892-6899. • Relevant and informative population-based study of patients with glioblastoma.
99. Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, Farina R, Farinotti M, Fariselli L, Finocchiaro G, Giombini S et al: Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol (2008) 10(1):79-87. (Pubitemid 351250903)